INS and type 2 diabetes mellitus: hAMSC‐sEV treatment increased insulin secretory capacity (Figure 3f–h), and the homeostasis model assessment of β‐cell function (HOMA‐β) was higher in sEV‐treated mice than in untreated T2DM controls (Figure 3i).